Oppenheimer & Co’s Alterity Therapeutics ATHE Stock Holding History

Oppenheimer & Co’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-333	Closed	-$56K	–	1410
2014 Q1	$56K	Buy	+333	New	+$184K	﹤0.01%	1373

Other funds holding ATHE

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oppenheimer & Co's ATHE Position: Q2 2014 in Review

Oppenheimer & Co sold out of Alterity Therapeutics (ATHE) in Q2 2014, closing a stake of 333 shares — an estimated $56K sold.

Oppenheimer & Co first reported a position in ATHE in Q1 2014 and held it in 1 quarter. The position peaked at $56K in Q1 2014. 26 funds tracked by Wall St. Rank hold ATHE as of Q2 2014.

Oppenheimer & Co reported no remaining Alterity Therapeutics position as of Q2 2014 after selling out during the quarter.
Oppenheimer & Co sold 333 Alterity Therapeutics shares in Q2 2014, an estimated $56K.
Oppenheimer & Co first reported a position in Alterity Therapeutics in Q1 2014 and held it in 1 quarter.
Oppenheimer & Co's Alterity Therapeutics position peaked at $56K in Q1 2014.
26 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2014.

Based on Oppenheimer & Co's 13F filing for Q2 2014, filed 14 Aug 2014.